Author

Siyang Ren

Dana-Farber Cancer InstituteORCID 0000-0002-8516-6047Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Approach:experimental assay· 2 Research Focus:benchmarking· 1 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Research Focus:gene regulatory network inference· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

Alan DenAdeliD· 1 shared Alejandro J. Gupta· 1 shared Alex K. ShalekiD· 1 shared Alexandria Van ScoykiD· 1 shared Alfred Thomas LookiD· 1 shared Alla Berezovskaya· 1 shared Amélie VrommaniD· 1 shared Andrew W. NaviaiD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan DenAdelORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ImmunologybioRxivPreprintJun 12, 2025

Multitargeted Reduction of Inflammation and Atherosclerosis in Tet2-deficient CHIP via XPO1 Inhibition and Atf3 restoration

Nicole Prutsch, Amélie Vromman, Brittaney A. Leeper…·Alfred Thomas Look

3 citations

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJun 6, 2024

Mutation and cell state compatibility is required and targetable in Ph+ acute lymphoblastic leukemia minimal residual disease

Peter S. Winter, Michelle L. Ramseier, Andrew W. Navia…·Mark Alan Murakami

This study identifies mutation and transcriptional state compatibility in Ph+ ALL MRD, showing that targeting these interactions can overcome BCR::ABL1 independence and improve MRD monitoring.

3 citations

humanbulk RNA-seq

𝕏 PostBluesky